Eradication of Helicobacter pylori by 7‐Day Triple‐Therapy Regimens Combining Pantoprazole with Clarithromycin, Metronidazole, or Amoxicillin in Patients with Peptic Ulcer Disease: Results of Two Double‐Blind, Randomized Studies
- 24 November 2003
- journal article
- clinical trial
- Published by Wiley in Helicobacter
- Vol. 8 (6), 626-642
- https://doi.org/10.1111/j.1523-5378.2003.00179.x
Abstract
Aim. To compare the short‐term (7‐day) safety and efficacy of two triple‐therapy regimens using pantoprazole with those of two dual‐therapy regimens (one with pantoprazole and one without), for Helicobacter pylori eradication in patients with peptic ulcer disease.Methods. H. pylori infection was identified by rapid urease (CLOtest), and confirmed by histology and culture. Patients were enrolled into one of two randomized, double‐blind, multicenter, parallel‐group studies. In study A, patients received oral pantoprazole 40 mg, clarithromycin 500 mg, and metronidazole 500 mg (PCM); pantoprazole, clarithromycin and amoxicillin 1000 mg (PCA); or pantoprazole and clarithromycin (PC). In study B, patients received PCM, PCA, PC, or clarithromycin and metronidazole without pantoprazole (CM). Treatments were given twice daily for 7 days. H. pylori status after therapy was assessed by histology and culture at 4 weeks after completing the course of study treatment. Modified intent‐to‐treat (MITT; each study: n = 424, n = 512) and per‐protocol (PP; each study: n = 371, n = 454) populations were analyzed. The MITT population comprised all patients whose positive H. pylori status was confirmed by culture and histology; the PP population comprised patients who also complied with ≥ 85% of study medication doses.Results. A total of 1016 patients were enrolled. Cure rates among patients with clarithromycin‐susceptible H. pylori strains were 82 and 86% for PCM, and 72 and 71% for PCA, in studies A and B, respectively. Cure rates among patients with metronidazole‐susceptible H. pylori strains were 82 and 87% for PCM, and 71 and 69% for PCA, in studies A and B, respectively. The combined eradication rates observed with the PCM regimen were superior to those of all other regimens tested. Side‐effects were infrequent and mild.Conclusions. PCM had the highest overall eradication rate in these two studies examining 7‐day treatment regimens. All regimens were safe and well tolerated.Keywords
This publication has 101 references indexed in Scilit:
- Current concepts in the management of Helicobacter pylori infection—The Maastricht 2‐2000 Consensus ReportAlimentary Pharmacology & Therapeutics, 2002
- Risk Factors for H. pylori Antimicrobial Resistance Partnership (SHARP) Study, 1993–1999Annals of Internal Medicine, 2002
- Clarithromycin-Susceptible and -Resistant Helicobacter pylori Isolates with Identical Randomly Amplified Polymorphic DNA-PCR Genotypes Cultured from Single Gastric Biopsy Specimens Prior to Antibiotic TherapyJournal of Clinical Microbiology, 2001
- Accurate Prediction of Macrolide Resistance in Helicobacter pylori by a PCR Line Probe Assay for Detection of Mutations in the 23S rRNA Gene: Multicenter Validation StudyAntimicrobial Agents and Chemotherapy, 2001
- Evaluation of Clarithromycin Resistance and cagA and vacA Genotyping of Helicobacter pylori Strains from the West of Ireland Using Line Probe AssaysJournal of Clinical Microbiology, 2001
- A multicentre study on eradication of Helicobacter pylori using four 1-week triple therapies in ChinaAlimentary Pharmacology & Therapeutics, 2001
- Triple therapy for Helicobacter pylori eradication: a comparison of pantoprazole once versus twice dailyAlimentary Pharmacology & Therapeutics, 2000
- Effect of Pretreatment Antibiotic Resistance to Metronidazole and Clarithromycin on Outcome of Helicobacter pylori TherapyDigestive Diseases and Sciences, 2000
- Comparison of two 3-day Helicobacter pylori eradication regimens with a standard 1-week regimenAlimentary Pharmacology & Therapeutics, 1999
- Metronidazole resistance in Helicobacter pylori is due to null mutations in a gene (rdxA) that encodes an oxygen‐insensitive NADPH nitroreductaseMolecular Microbiology, 1998